Sign in
Taking people in United StatesPhase 1

Tests immune cells with chemotherapy in children with neuroblastoma or osteosarcoma

Tests donor immune cells with drugs in children whose cancer returned or stopped responding.

Key facts

Who runs it
Emory University
Where
Atlanta, United StatesSee the site
Trial code
Registry title
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
Status
Recruiting
Phase
Phase 1
People taking part
24 people, planned
Started
6 Nov 2023
Expected to end
Dec 2026
Type of study
Interventional
Treatments tested
  • Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
Record updated
26 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people with neuroblastoma or osteosarcoma that did not respond to treatment, came back, or got worse.

Age
12 months or older
Sex
All sexes
Disease stage
High-risk neuroblastoma that is refractory, relapsed or progressing, or osteosarcoma that is relapsed or refractory and not responsive to standard treatment. The disease must be measurable or evaluable.
Earlier treatment
Must have fully recovered from the acute side effects of earlier chemotherapy, immunotherapy or radiotherapy. Earlier dinutuximab, temozolomide, zoledronate or dinutuximab/temozolomide/irinotecan treatment is allowed. Earlier T cell therapy is not allowed.

Main reasons for not taking part

  • Prior T cell therapy
  • Pregnancy or breastfeeding
  • Prior allogeneic stem cell transplant
  • Known active central nervous system disease
  • Known history of HIV, hepatitis B or hepatitis C

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Patients must be ≥ 12 months of age at the time of enrollment in the study
  • Diagnosis: Histological confirmation of neuroblastoma or ganglioneuroblastoma at initial diagnosis. (Bone marrow samples with positive catecholamines are acceptable as confirmation of neuroblastoma) OR histological confirmation of osteosarcoma at diagnosis
  • Response to prior therapy:; High-risk neuroblastoma with refractory, relapsed or progressive disease, defined as:; First or greater relapse of neuroblastoma following completion of aggressive multi- drug frontline therapy; First episode of progressive neuroblastoma during aggressive multi-drug frontline therapy; Persistent/refractory neuroblastoma as defined by less than a complete response by the revised International Neuroblastoma Response Criteria (INRC) after at least 4 cycles of aggressive multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol (such as A3973 or ANBL0532); Note that this excludes patients initially considered low or intermediate-risk neuroblastoma that progressed to high-risk disease but the patient has not progressed after the diagnosis of high-risk neuroblastoma; Relapsed or refractory osteosarcoma that is not responsive to standard treatment
  • Disease Status; Patients must have measurable or evaluable disease per revised INRC for subjects with neuroblastoma or measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for subjects with Osteosarcoma; Performance Level:Patients must have a Lansky (≤16 years) or Karnofsky (>16 years) score of ≥50
  • Prior Therapy; Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy before study registration; Prior dinutuximab therapy is allowed regardless of prior response or progression on dinutuximab; Prior temozolomide therapy is allowed; Prior zoledronate is allowed; Prior dinutuximab/temozolomide/irinotecan chemoimmunotherapy is allowed; Prior T cell therapy is excluded
  • Organ Function Requirements:; Hematologic Functions : Absolute Neutrofil count ≥750/uL and platelet count ≥ 75,000/µl, transfusion independent ; Renal Function: Patients must have adequate renal function defined as age-adjusted serum creatinine ≤1.5 ULN for age; Liver Function: Total bilirubin ≤ 1.5 x ULN for age and serum glutamic-pyruvic transaminase (SGPT) (ALT) ≤ 135 U/L (≤ 3x ULN); Cardiac Function: Normal ejection fraction (≥ 55%) documented by either echocardiogram or radionuclide multigated acquisition scan (MUGA) evaluation OR Normal fractional shortening (≥ 27%) documented by echocardiogram; Pulmonary Function: Normal pulmonary function with no evidence of dyspnea at rest, no exercise intolerance

Who cannot take part

  • Prior T cell therapy
  • Patients with prior allogeneic stem cell transplant
  • Patients who have received any live vaccines within 30 days before enrollment
  • Patients with known active Central Nervous System (CNS) disease (excluding skull disease with intracranial extension). Patients with a history of CNS disease are required to have a brain CT and/ or MRI at study registration
  • Patients with an active or uncontrolled infection. Patients on prolonged antifungal therapy are still eligible if they are culture negative, afebrile, and meet other organ function criteria
  • Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C. Testing is not required in the absence of clinical findings or suspicion
  • Patients with disease of any major organ system that would compromise their ability to withstand therapy
  • Patients with serious, uncontrolled cardiac arrhythmias
  • Patients with a history of myocarditis
  • Pregnancy, breast feeding, or unwillingness to use effective contraception during the study will not be entered on this study
  • Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
  • Patients who are on hemodialysis
  • Patients who have had to permanently discontinue Dinutuximab due to toxicity

Where in United States

  • Children's Healthcare of AtlantaAtlanta, United StatesContact: Kelly Goldsmith, MDTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of allogeneic expanded γδ T cells when delivered with Dinutuximab, temozolomide, irinotecan, and zoledronate in children with refractory or recurrent neuroblastoma or refractory/ relapsed osteosarcoma as well as to define the toxicities of allogeneic expanded γδ T cells when delivered with Dinutuximab, temozolomide, irinotecan, and zoledronate

The group in the trial

  • Dose Escalation Phase I cohortTreatment being tested

    Subjects are assigned a cell therapy dose level at registration. Entry dose is Level 1, with escalation to Level 3 using a 3+3 design. If no progression, up to 4 courses may be given. Each course includes two γδ T cell infusions, one week apart. Toxicity for dose escalation and MTD will be assessed in Course 1. Disease response will be evaluated after Courses 2 and 4. Dinutuximab (17.5 mg/m²), temozolomide (100 mg/m²), irinotecan (50 mg/m²), and zoledronate (0.0125 mg/kg) are consistent across dose levels. Same γδ T cell donor will be used for both infusions per course. Due to stock supply, this may not always be possible. In each cohort, the first two subjects are staggered; the second is enrolled only after the first completes the DLT observation (≥21 days).

    Treatment: Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I Study of Allogeneic Ex Vivo Expanded Gamma Delta (γδ) T Cells in Combination With Dinutuximab, Temozolomide, Irinotecan, and Zoledronate in Children With Refractory/ Relapsed, or Progressive Neuroblastoma or Refractory/ Relapsed Osteosarcoma
Plain-language title
Tests immune cells with chemotherapy in children with neuroblastoma or osteosarcomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 December 2025